Context Therapeutics is trading 7.23% up at $0.26 in pre-market on October 16, 2026, with no verified catalyst established.
- Shares closed at $0.24 on October 15 and rose 12.27% after-hours that day.
- No new company announcement explaining the pre-market move surfaced; the CT-202 first-patient dosing announcement was published September 9.
- Broader market indicators are mixed and do not clearly account for the move.